The ROE as of November 2024 (TTM) for Tekla Life Sciences Investors (HQL) is 9.07%

According to Tekla Life Sciences Investors’s latest financial reports and current stock price. The company's current ROE is 9.07%. This represents a change of 119.21% compared to the average of 4.14% of the last 4 quarters.

Tekla Life Sciences Investors (HQL) Historical ROE (quarterly & annually)

How has HQL ROE performed in the past?

The mean historical ROE of Tekla Life Sciences Investors over the last ten years is 4.54%. The current 9.07% ROE has changed 99.75% with respect to the historical average. Over the past ten years (40 quarters), HQL's ROE was at its highest in in the September 2020 quarter at 19.20%. The ROE was at its lowest in in the March 2022 quarter at -17.52%.

Tekla Life Sciences Investors (HQL) ROE by Quarter and Year

Discovering the peaks and valleys of Tekla Life Sciences Investors ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tekla Life Sciences Investors (HQL) Average ROE

How has HQL ROE performed in the past?

The current ROE of Tekla Life Sciences Investors (HQL) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Tekla Life Sciences Investors (HQL) ROE vs. Peers

How is HQL’s ROE compared to its peers?

Tekla Life Sciences Investors’s ROE is less than Tekla World Healthcare Fund (10.57%), less than Tekla Healthcare Opportunities Fund (13.07%), less than Royce Value Trust Inc. (12.08%), less than John Hancock Financial Opportunities Fund (35.17%), less than Tekla Healthcare Investors (6.13%), less than Flaherty & Crumrine Dynamic Preferred and Income Fund Inc. (17.11%), less than Cohen & Steers Infrastructure Fund, Inc (5.68%), less than Eaton Vance Tax-Advantaged Global Dividend Income Fund (16.16%), greater than BlackRock MuniYield Fund, Inc. (-0.96%), less than Eaton Vance Tax-Advantaged Dividend Income Fund (12.98%), less than Eaton Vance Tax-Managed Buy-Write Income Fund (13.67%), less than Nuveen California Select Tax-Free Income Portfolio (12.50%), less than Cohen & Steers REIT and Preferred Income Fund, Inc. (14.46%), less than XAI Octagon Floating Rate & Alternative Income Term Trust (20.60%), less than Nuveen Preferred and Income Term Fund (13.67%), less than First Trust Intermediate Duration Preferred & Income Fund (16.01%), less than Flaherty & Crumrine Preferred Securities Income Fund Inc. (19.87%), less than Eaton Vance Risk-Managed Diversified Equity Income Fund (18.34%),

Build a custom stock screener for Tekla Life Sciences Investors (HQL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tekla Life Sciences Investors using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tekla Life Sciences Investors (HQL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tekla Life Sciences Investors or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.